6th Annual IBDHorizons Midwest Symposium
IBDHorizons is pleased to announce the 5th Annual IBD-focused Midwest Symposium, Now in Cincinnati
IBDHorizons provides free IBD conferences open to all those who treat IBD, desire to treat IBD, and who face IBD.
At our 6th Annual Midwest IBD conference, you will learn from and engage in discourse about the latest in Inflammatory Bowel Disease (IBD) from world-renowned faculty, on Saturday, February 11, 2023.
During the IBDHorizons Northwest Symposium, you’ll be provided with a smooth experience including catered meals, thoughtful breaks throughout the day’s events, and a personal tablet to engage with the presentations. We dedicate more time than most other IBD conferences to our open panel discussions and real-world case studies to be examined alongside the faculty.
Our Midwest IBD conference will be hosted at the Hyatt Regency, 151 West 5th Street, Cincinnati, OH.
This IBDHorizons event will be accredited for up to 6 CME, CE, and CPE credit hours for attendees.
Registration is required to plan accordingly, but registration for IBDHorizons Midwest is complimentary to attendees!
Join us for this amazing IBD conference opportunity to engage with key/known/notable leaders in the field of Inflammatory Bowel Disease (IBD).
IBDHorizons IBD-dedicated conference presents an excellent opportunity for industry exhibits. Please contact us for more information.
Speakers and topics are to be announced soon! As always, our IBD Founders and honorary board member Dr. Brian Feagan will be speaking.
Research Plenary Session
Returning this year is our Abstract presentations and Research Plenary Session. The deadline for submission of abstracts will be announced in the coming months.
Anita Afzali, MD, MPH, MHCM Professor of Clinical Medicine, Executive Vice Chair of Medicine in the Department of Internal Medicine at the University of Cincinnati College of Medicine, Associate Chief Medical Officer of the UC Health System and Cincinnati Children's HospitalAnita Afzali, MD, MPH, MHCMProfessor of Clinical Medicine, Executive Vice Chair of Medicine in the Department of Internal Medicine at the University of Cincinnati College of Medicine, Associate Chief Medical Officer of the UC Health System and Cincinnati Children's Hospital
Dr. Anita Afzali is a Professor of Clinical Medicine in the Division of Digestive Diseases and Executive Vice Chair of Medicine in the Department of Internal Medicine at the University of Cincinnati College of Medicine. Dr. Afzali is also the Associate Chief Medical Officer of the UC Health System and Cincinnati Children’s Hospital.
She remains an Adjunct Professor of Medicine at OSU.
Dr. Afzali holds the Abercrombie & Fitch Endowed Chair in Inflammatory Bowel Disease. She received her medical degree and then completed an Internal Medicine residency and Gastroenterology fellowship at the University of Washington in Seattle, WA. While in fellowship, Dr. Afzali worked in outcomes research and epidemiology, and also graduated with a Master’s in Public Health. Her sub-specialty training includes a one-year advanced IBD fellowship at the University of Washington, prior to becoming faculty. While practicing at the University of Washington – Harborview Medical Center, Dr. Afzali served as the Director of the IBD Program and Associate Medical Director of Gastroenterology Clinics at The Ohio State University.
Her research interests include clinical outcomes and association of bowel and joint disease, the influence of the metabolic syndrome and impact of race/ethnicity in IBD, as well as pharmacoeconomics, pediatric-to-adult transition, and women of childbearing age with IBD. She is also extensively involved in IBD clinical trials for investigational therapies. She has extensive peer-reviewed publications, an invited lecturer on national and international programs, and serves on several international advisory boards and committees including Co-Chair of the Crohn’s & Colitis National Professional Education Committee and Member of the ACG Minority Affairs and Cultural Diversity Committee.
Brian Feagan, MD, MSc Professor of Medicine at the Schulich School of Medicine & Dentistry in London, Ontario, Senior Scientific Director of Alimentiv IncBrian Feagan, MD, MScProfessor of Medicine at the Schulich School of Medicine & Dentistry in London, Ontario, Senior Scientific Director of Alimentiv Inc
Dr. Brian Feagan is a gastroenterologist, with training in Clinical Epidemiology and Biostatistics. His research focus is the design, conduct, and execution of large-scale randomized controlled trials (RCTs) in Crohn’s disease (CD) and ulcerative colitis (UC), and over the past 30 years, has been Principal Investigator in over 140 multi-center RCTs. His research has been devoted to the development, validation, and optimization of outcome measures to assess the efficacy of novel therapeutics in CD and UC. Dr. Feagan is Professor of Medicine at the Schulich School of Medicine & Dentistry, a gastroenterologist at London Health Sciences Centre and Senior Scientific Director of Alimentiv Inc (formerly Robarts Clinical Trials Inc).
Brian G. Feagan completed a medical degree at the University of Western Ontario in London, Ontario, Canada. His postdoctoral training included a residency in the Department of Medicine and a fellowship in Gastroenterology at the University of Western Ontario. A Fellow of the Royal College of Physicians and Surgeons of Canada, Dr. Feagan holds membership in the Canadian and American Association of Gastroenterology, the American College of Gastroenterology, the College of Physicians and Surgeons of Ontario, Crohn’s and Colitis Canada (CCC), and the European Crohn’s & Colitis Organization (ECCO). He is the recipient of the 2013 Senior Achievement Award from the Crohn’s & Colitis Foundation of America (CCFA) and the Dean’s Award of Excellence in 2013 from the University of Western Ontario. He has authored over 200 articles, book chapters and has also given over 900 invited presentations, at national and international scientific meetings. In 1997, Dr. Feagan became Director of Robarts Clinical Trials (now Alimentiv, Inc.).
Ghassan WahbehMD, Director of the Inflammatory Bowel Disease Center at Seattle Children’s Hospital
Ghassan Wahbeh, MD, is the director of the Inflammatory Bowel Disease Center at Seattle Children’s Hospital. He is a Professor of Pediatrics and Gastroenterology at the University of Washington School of Medicine. Dr. Wahbeh’s clinical focus is in advanced care for children, adolescents, and young adults with Crohn’s Disease and Ulcerative Colitis, including advanced therapeutics and pre and post-surgery IBD management.
Dr. Wahbeh’s research interests include advanced management of moderate and severe colitis in the outpatient and inpatient setting, managing complicated Crohn’s disease including fistulizing and stricturing phenotypes, mucosal healing in IBD, navigating surgical options in IBD and novel therapies. Dr. Wahbeh is actively involved as teaching faculty in medical student education, resident training, and fellow physician specialty training. He is the honored recipient of the Outstanding Teaching Faculty Award, as well as the Family Choice Award, and the Northwest Crohns & Colitis Foundation service award. He continues to serve as a member of the National Professional Education Committee and the Northwest Medical Advisory Committee of the Crohns and Colitis Foundation of America.
Scott D. Lee MD Associate Professor of Medicine, Director, Clinical Inflammatory Bowel Disease Program at University of Washington Medical CenterScott D. Lee MDAssociate Professor of Medicine, Director, Clinical Inflammatory Bowel Disease Program at University of Washington Medical Center
Dr. Scott D. Lee is an associate professor of medicine with expertise in inflammatory bowel disease (Crohn’s disease and ulcerative colitis). Dr. Lee earned his bachelor’s degree at Pomona College and his M.D. at Jefferson Medical College. He completed his residency in internal medicine at the University of Colorado in Denver. After residency, Dr. Lee completed his gastroenterology fellowship at the University of Washington. After completing his fellowship, he attended the University of Chicago and Cedar-Sinai in Los Angeles as a visiting physician to gain additional training in IBD. Since finishing his fellowship, he has been an attending gastroenterology physician at the University of Washington Medical Center. Currently, his clinical practice is at the Digestive Disease Center at the University of Washington and is dedicated exclusively to providing care to patients with the diagnosis of IBD. His research is focused on inflammatory bowel diseases (IBD) including – new therapies for IBD, improving outcomes in the treatment and long-term management of IBD, evaluation of non-invasive biomarkers to assess disease activity in IBD patients, and the effects of the microbiome on IBD. He has participated in more than 100 clinical trials in IBD and continues to have an active clinical research program. He is a member of the Crohn’s Colitis Foundation of America (CCFA), American Gastroenterology Association, American College of Gastroenterology, and American Society of Gastrointestinal Endoscopy. He is a past chair of Northwest CCFA Chapter Medical Advisory Committee (CMAC) and continues as a current member of the CMAC.